Section Arrow
MRUS.NASDAQ
- Merus NV
Quotes are at least 15-min delayed:2025/07/21 06:40 EDT
Pre Market
Last
 63.87
+0.61 (+0.96%)
Bid
46.08
Ask
90
High 65 
Low 62.3 
Volume 89 
Regular Hours
Last
 63.26
+1.82 (+2.96%)
Day High 
63.43 
Prev. Close
61.44 
1-M High
61.53 
Volume 
1.06M 
Bid
46.08
Ask
90
Day Low
61.325 
Open
61.88 
1-M Low
51.78 
Market Cap 
4.58B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 55.14 
20-SMA 54.13 
50-SMA 51.23 
52-W High 63.43 
52-W Low 33.19 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.16/-3.31
Enterprise Value
4.58B
Balance Sheet
Book Value Per Share
8.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.13M
Operating Revenue Per Share
0.61
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.01 -0.27 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.21 -0.865 -6.15%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.21 +0.37 +6.34%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed:2025/07/21 06:40 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.